Allisartan isoproxil, a blocker of the angiotensin II receptor that is used to reduce the risk of heart disease, mitigates diabetes-induced OS and inflammation by upregulating Sirt1/Nrf2/HO-1 signal and inhibiting the NF-κB activation, respectively, in diabetic cardiomyopathy (DCM) rats [37]. The gene discussed is NFKB1; the disease is diabetes mellitus.